# REPRIEVE COVID-19 Administrative Supplement

> **NIH NIH U01** · MASSACHUSETTS GENERAL HOSPITAL · 2020 · $1,210,912

## Abstract

Project Summary
In response to NOT-HL-20-757, Notice of Special Interest (NOSI): Availability of Administrative Supplements
and revision Supplements on Coronavirus Disease 2019 (COVID-19), and PA-18-591 Administrative
Supplements for existing NIH Grants and Cooperative Agreements, the enclosed administrative supplement,
leveraging parent grant U01 HL123336, is submitted for consideration. Understanding COVID-related CV
complications in at-risk populations represents an urgent national priority. Retrospective case series have
shown that among patients in the general population hospitalized with COVID-19, approximately 20 to 30%
evidence myocardial injury, which is associated with adverse outcomes including cardiac dysfunction,
arrythmia, hypercoagulable events, and death. In addition, significant evidence exists for endothelial and
vascular dysfunction related to COVID-19, related to membrane uptake via ACE-2 or other mechanisms.
People with HIV (PWH) already face increased risk of myocardial infarction and heart failure as compared with
the general population. How COVID-19 affects CV morbidity and mortality among PWH remains unknown and
preventive/therapeutic strategies have yet to be identified. We propose to leverage the REPRIEVE trial – the
largest international randomized trial focused on preventing HIV-associated CV disease – to address critical
knowledge gaps regarding SARS-CoV-2 infection and COVID-related CV complications among PWH. Studying
7,700 PWH ages 40-75 across 5 continents, we will focus on three interrelated but independent key topics:
epidemiology, host factors, and protective strategies. In this regard, statins have pleiotropic effects and
potently reduce vascular inflammation and improve endothelial function, The results of the supplement will
provide critical information on HIV and COVID-19, and conversely critical effects of statins to mitigate effects of
the SARS-Co-V2 virus on cardiovascular disease and endothelial function, and MACE. These results will be
broadly generalizable to the large population of HIV patients simultaneously at risk for COVID-19 and CVD and
also to other populations at risk for CVD experiencing COVID infection.

## Key facts

- **NIH application ID:** 10149693
- **Project number:** 3U01HL123336-06S2
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** Pamela Susan Douglas
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,210,912
- **Award type:** 3
- **Project period:** 2014-08-08 → 2023-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10149693

## Citation

> US National Institutes of Health, RePORTER application 10149693, REPRIEVE COVID-19 Administrative Supplement (3U01HL123336-06S2). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10149693. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*